


ANGEL ACQUISITION APS

ÅKANDEVEJ 21, 2700 BRØNSHØJ

ANNUAL REPORT

1. JANUAR - 31. DECEMBER 2016

The Annual Report has been presented and
adopted at the Company's Annual General
Meeting on 21 June 2017



Anders Birkebæk Clausen

CONTENTS

	Page
Company Details	
Company Details.....	3
Statement and Report	
Statement by Board of Executives.....	4
Independent Auditor's Report.....	5-6
Management's Review	
Financial Highlights.....	7
Management's Review.....	8
Financial Statements 1 January - 31 December	
Income Statement.....	9
Balance Sheet.....	10-11
Equity.....	12
Notes.....	13-15
Accounting Policies.....	16-18

COMPANY DETAILS

Company	Angel Acquisition ApS Åkandevej 21 2700 Brønshøj CVR no.: 33 37 52 98 Established: 22 December 2010 Registered Office: Brønshøj Financial Year: 1 January - 31 December
Board of Executives	Frank T. McFaden
Auditor	Ernst & Young Godkendt Revisionspartnerselskab Osvold Helmuhs Vej 4 2000 Frederiksberg

STATEMENT BY BOARD OF EXECUTIVES

Today the Board of Executives have discussed and approved the Annual Report of Angel Acquisition ApS for the year 1 January - 31 December 2016.

The Annual Report is presented in accordance with the Danish Financial Statements Act.


In my opinion the financial statements give a true and fair view of the Company's financial position at 31 December 2016 and of the results of the Company's operations for the financial year 1 January - 31 December 2016.

Further, in my opinion, the Management's review gives a fair review of the development in the Company's operations and financial matters and the results of the Company's operations and financial position.

I recommend that the Annual Report be approved at the Annual General Meeting.

Copenhagen, 21 June 2017

Board of Executives



Frank T. McFaden

INDEPENDENT AUDITOR'S REPORT

To the Shareholder of Angel Acquisition ApS

Opinion

We have audited the financial statements of Angel Acquisition ApS for the financial year 1 January - 31 December 2016, which comprise income statement, balance sheet, statement of changes in equity and notes including a summary of significant accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.

In our opinion, the financial statements give a true and fair view of the financial position of the Company at 31 December 2016 and of the results of the Company operations for the financial year 1 January - 31 December 2016 in accordance with the Danish Financial Statements Act.

Basis for Opinion

We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the "Auditor's Responsibilities for the audit of the financial statements" section of our report. We are independent of the Company in accordance with the International Ethics Standards Board for Accountants' Code of Ethics for Professional Accountants (IESBA Code) and additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these rules and requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Management's Responsibility for the financial statements

Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act and for such Internal control as Management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, Management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting in preparing the financial statements unless Management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Auditor's Responsibilities for the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by Management.

INDEPENDENT AUDITOR'S REPORT

- Conclude on the appropriateness of Management's use of the going concern basis of accounting in preparing the financial statements and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusion is based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and contents of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that gives a true and fair view.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Statement on Management's review

Management is responsible for Management's review.

Our opinion on the financial statements does not cover Management's review, and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read Management's review and, in doing so, consider whether Management's review is materially inconsistent with the financial statements or our knowledge obtained during the audit, or otherwise appears to be materially misstated.

Moreover, it is our responsibility to consider whether Management's Review provides the information required under the Danish Financial Statements Act.

Based on the work we have performed, we conclude that Management's Review is in accordance with the financial statements and has been prepared in accordance with the requirements of the Danish Financial Statements Act. We did not identify any material misstatement of Management's Review.

Copenhagen, 21 June 2017

Ernst & Young Godkendt Revisionspartnerselskab
CVR-nr. 30 70 02 28


Henrik Kronborg Iversen
State Authorised Public Accountant


Rasmus Bloch Jespersen
State Authorised Public Accountant

FINANCIAL HIGHLIGHTS

	2016 USD '000	2015 USD '000	2014 USD '000	2013 USD '000	2012 USD '000
Income statement					
Operating loss.....	-39	-44	-38	-52	-180
Financial income and expenses, net.....	-46.542	-44.652	-42.201	-7.810	-42.182
Profit/loss for the year.....	410.138	1.732.724	-42.239	-7.878	-42.320
Dividend income.....	456.719	1.777.420	0	0	0
Balance sheet					
Balance sheet total.....	6.478.604	6.345.515	6.371.240	6.405.340	34.086.184
Equity.....	5.874.601	5.594.317	5.664.987	5.741.325	30.470.709
Ratios					
Solvency ratio.....	90,7	88,2	88,9	89,6	89,4
Return on equity.....	7,2	30,8	Neg.	0,0	Neg.

The ratios stated in the list of key figures and ratios have been calculated as follows:

Solvency ratio:

$$\frac{\text{Equity, at year end} \times 100}{\text{Total equity and liabilities, at year end}}$$

Return on equity:

$$\frac{\text{Profit/loss after tax} \times 100}{\text{Average equity}}$$

The key figures are prepared in accordance with the guidance of The Danish Finance Society (Den danske Finansanalytikerforening) on "Recommendation & Key Figures 2015". Reference is made to survey of principal figures and key figures concerning the formula for calculation of individual key figures.

MANAGEMENT'S REVIEW

Principal activities

The objectives of the company are to carry on commercial and manufacturing business as well as financing and investment.

Specifically the company holds investments in group enterprises.

Development in activities and financial position

The Company's income statement for the year ended 31 December 2016 shows a net profit of USD 410,138 thousand, and the balance sheet at 31 December 2016 shows equity of USD 5,874,601 thousand.

In the annual report 2015 management expressed an expected profit for 2016 at same level as in 2015 (profit of USD 1,732,724 thousand). The realised profit for 2016 was, in comparison to the prior years expressed expectations, impacted by less dividend income from investments in subsidiaries.

The Executive Board recommends distribution of the profit as stated under distribution of profit.

Significant events after the end of the financial year

No events of material importance for the company's financial position have occurred after the end of the financial year.

Special risks

Interest rate risk

The interest rate on its loans is on market terms and conditions.

Apart from the above the Company is not exposed to any special risks, which could significantly impact future earnings.

Future expectations

The company expects earnings for 2017 before any dividend income from investments, at the same level as for 2016 (+/- 10%).

Corporate social responsibility

As the company is a holding company without significant operating activities, policies involving environmental, climate and human rights etc. are not prepared.

Target figures and policies for the underrepresented gender

As the company's management comprise of one executive and no Board of Directors or other employees, no target figures and policies for the gender composition cf., the Act on Gender Equality, has been set.

INCOME STATEMENT 1 JANUARY - 31 DECEMBER

	Note	2016 USD '000	2015 USD '000
Other external expenses.....	1	-39	-44
GROSS LOSS.....		-39	-44
OPERATING LOSS.....		-39	-44
Dividend income from investments in group enterprises.....		456.719	1.777.420
Other financial income.....	2	270	262
Other financial expenses.....	3	-46.812	-44.914
PROFIT BEFORE TAX.....		410.138	1.732.724
Tax on profit for the year.....		0	0
PROFIT FOR THE YEAR.....	4	410.138	1.732.724

BALANCE SHEET AT 31 DECEMBER

ASSETS	Note	2016 USD '000	2015 USD '000
Investments in group enterprises.....		6.324.604	6.324.604
Fixed asset investments.....	5	6.324.604	6.324.604
FIXED ASSETS.....		6.324.604	6.324.604
Receivables from group enterprises.....		150.815	0
Receivables.....		150.815	0
Cash and cash equivalents.....		3.185	20.911
CURRENT ASSETS.....		154.000	20.911
ASSETS.....		6.478.604	6.345.515

BALANCE SHEET AT 31 DECEMBER

EQUITY AND LIABILITIES	Note	2016 USD '000	2015 USD '000
Share capital.....		2.921	2.921
Retained profit.....		5.720.865	5.461.542
Proposed dividend.....		150.815	129.854
EQUITY.....		5.874.601	5.594.317
Payables to group enterprises.....		603.809	714.666
Long-term liabilities.....	6	603.809	714.666
Bank debt.....		179	138
Trade payables.....		15	26
Payables to group enterprises.....		0	36.368
Current liabilities.....		194	36.532
LIABILITIES.....		604.003	751.198
EQUITY AND LIABILITIES.....		6.478.604	6.345.515
 Contingencies etc.	 7		
Related parties	8		
Consolidated financial statements	9		

EQUITY

	Share capital	Retained profit	Proposed dividend	Total
Equity at 1 January 2016.....	2.921	5.461.542	129.854	5.594.317
Dividend paid.....			-129.854	-129.854
Proposed distribution of profit.....		259.323	150.815	410.138
Equity at 31 December 2016.....	2.921	5.720.865	150.815	5.874.601

Changes in share capital in the latest 5 years, T. DKK

	2016	2015	2014	2013	2012
Balance at 1 January.....	15.026	15.026	15.026	15.026	15.026
Balance at 31 December.....	15.026	15.026	15.026	15.026	15.026

NOTES

	2016 USD '000	2015 USD '000	Note
Fee to statutory auditors			1
Total fee:			
Ernst & Young.....	16	16	
	16	16	
Specification of audit fee:			
Statutory audit.....	16	16	
	16	16	
Other financial income			2
Other interest income.....	270	262	
	270	262	
Other financial expenses			3
Interest, group enterprises.....	46.810	44.913	
Other interest expenses.....	2	1	
	46.812	44.914	
PROPOSED DISTRIBUTION OF PROFIT			4
Proposed dividend for the year.....	150.815	129.854	
Extraordinary dividend distributed in the year.....	0	1.772.394	
Accumulated profit.....	259.323	-169.524	
	410.138	1.732.724	
Fixed asset investments			5
		Investments in group enterprises	
Cost at 1 January 2016.....		6.324.604	
Cost at 31 December 2016.....		6.324.604	
Carrying amount at 31 December 2016.....		6.324.604	

NOTES

Note

Impairment test

Management has prepared an impairment test and thereby calculated the recoverable amount of the Company's investment in group enterprises at 31 December 2016.

The impairment method used is based on Danaher's standard internal valuation methodology. This method is based on the financial reporting as of 31 December 2016, and representative EBITDA multiplied by an assessed multiplier based on a peer-group analysis, adjusted for control premiums if applicable and non-operating assets/liabilities. The impairment test did not result in need for impairment.

Investments in group enterprises

Name, country of domicile, equity and profit/loss disclosures for the subsidiaries are based on financial statements for 2015 and 2016 for the respective subsidiaries. Where the financial statements are not available the internal financial reporting is used. Reference is made to addendum to note 5 on page 19-21.

Long-term liabilities

	1/1 2016 total liabilities	31/12 2016 total liabilities	Repayment next year	Debt outstanding after 5 years
Payables to group enterprises..	714.666	603.809	0	603.809
	714.666	603.809	0	603.809

6

Contingencies etc.

Joint taxation

The company is jointly taxed with Danaher Tax Administration ApS, which is the management company (Administrationselskab) for the Danish joint taxation. The company is jointly and severally unlimited liable with the other jointly taxed companies for payment of corporation tax for the income year 2013 and later, and for withholding tax on interest, royalties and dividends, which are payable on 1 July 2012 or later.

At 31 December 2016, the jointly taxed companies' net liability to SKAT is disclosed in the annual report for Danaher Tax Administration ApS, registration number - 28 31 68 87. Any subsequent assessments of the taxable income subject to joint taxation or withholding taxes on dividends, interest and royalties may entail that the Company's liability will increase.

Other contingencies

The company has no other contingent assets or liabilities.

Contingent assets

The Company has an unrecognised tax asset of USD 465 thousand (2015: USD 515 thousand), at a tax rate of 22% (2015: 22%).

The Company's deferred tax asset has not been recognised in the balance sheet due to uncertainties as to the future utilisation of the tax losses carry forward.

7

NOTES

	Note
Related parties	8

Related parties having performed transactions with the company

The company's related parties having a significant influence comprise subsidiaries and associates as well as the companies' Board of Directors, Board of Executives and executive officers and their relatives. Related parties include also companies in which the above mentioned group of persons has material interests.

Transactions with related parties

The related parties transactions for 2016 are shown below. All amounts in T.USD

Transactions	Parent company	Group enterprises
Administration, cost		19
Dividend received		456.719
Dividend paid	129.854	
Interest paid		46.810
Loans repaid		194.033
Balances per 31.12.16		
Loan receivable	150.815	
Loans payable		603.809

Consolidated financial statements

The ultimate parent of the group is:

Danaher Corporation
 2200 Pennsylvania Avenue, NW
 Suite 800W
 Washington, DC 20037
 USA

The consolidated financial statement for the Danaher group can be acquired at the following link:

<https://www.sec.gov/Archives/edgar/data/313616/000031361617000066/dhr-20161231x10xk.htm>

ACCOUNTING POLICIES

The annual report of Angel Acquisition ApS for 2016 has been presented in accordance with the provisions of the Danish Financial Statements Act for enterprises in reporting class C, large enterprise.

Reclassification changes have been made in the financial statements regarding classification of intercompany debt and dividend income from investments in group enterprises. The comparative figures have been restated to reflect the classification change. In the balance sheet, payable to group enterprises of USD 714,666 thousand at 31 December 2015, previously incorrectly presented as current liabilities, have been reclassified to "Payable to group enterprises" under long-term liabilities. In the income statement, dividend income from investments in group enterprises of USD 1,777,420 thousand, presented as other financial income in 2015, have been reclassified to "Dividend income from investments in group enterprises".

The reclassification changes have not affected the results of operations or equity.

Effective 1 January 2016, the Company has adopted act no. 738 of 1 July 2015. This implies changes in the recognition and measurement in the following area:

Dividend from investments in subsidiaries

Dividend from investments in subsidiaries must always be recognised in the income statement going forward. If the carrying amount of the net assets of subsidiaries exceeds cost, or if dividend exceeding the profit for the year is distributed, there will be evidence of impairment, meaning that an impairment test must be conducted. Previously, dividend exceeding the subsidiary's accumulated earnings would be set off against cost.

Due to amendments to the Danish Financial Statements Act, the Company has changed reporting class, from class B to class C, which has solely implied new or changed presentation and disclosure requirements, which have been incorporated in the financial statements.

None of the above changes impacts on the income statement or the balance sheet for 2016 or the comparative figures.

Apart from the above new and changed presentation and disclosure requirements, which follow from act. no. 738 of 1 June 2015, the accounting policies are consistent with those of last year.

Consolidated financial statements

Referring to section 112(1) of the Danish Financial Statements Act, no consolidated financial statements are prepared. The financial statements for Angel Acquisition ApS and its group entities are part of the consolidated financial statements for Danaher Corporation, USA.

INCOME STATEMENT

Other external expenses

Other external expenses include expenses related to administration etc.

Investments in subsidiaries

Dividend from investments in subsidiaries is recognised in the income statement in the year of declaration. Distributions of dividend where the dividend exceeds the profit for the year or where the carrying amount of the Company's investments in the subsidiary exceeds the carrying amount of the subsidiary's net asset value will be evidence of impairment, meaning that an impairment test must be conducted.

ACCOUNTING POLICIES

Financial income and expenses in general

Financial income and expenses include interest income and expenses, realised and unrealised gains and losses arising from investments in financial assets, debt and transactions in foreign currencies, amortisation of financial assets and liabilities as well as charges and allowances under the tax-on-account scheme etc. Financial income and expenses are recognised in the income statement by the amounts that relate to the financial year.

Tax on profit for the year

The tax for the year, which consists of the current tax for the year and changes in deferred tax, is recognised in the income statement by the portion that may be attributed to the profit for the year, and is recognised directly in the equity by the portion that may be attributed to entries directly to the equity.

The company is jointly taxed with affiliated Danish enterprises. The current Danish corporation tax is distributed between the jointly taxed Danish enterprises in proportion to their taxable income, and with full distribution with refund regarding taxable losses. The jointly taxed companies are included in the tax-on-account scheme.

BALANCE SHEET

Fixed asset investments

Equity investments in subsidiaries are measured at cost. In case of indication of impairment, an impairment test must be conducted. Investments are written down to the lower of the carrying amount and the recoverable amount.

Impairment of fixed assets

The carrying amount of fixed assets investments, are tested valued on an annual basis for indications of impairment.

In the event of impairment indications, an impairment test is made for each asset or group of assets, respectively. If the net realisable value is lower than the carrying amount, write-down is provided to the lower value.

The recoverable amount is calculated at the higher of net selling price and capital value. The capital value is determined as the fair value of the expected net cash flows from the use of the asset or group of assets and the expected net cash flows from sale of the asset or group of assets after the end of its useful life.

Receivables

Receivables are measured at amortised cost which usually corresponds to nominal value. The value is reduced by write-down to meet expected losses.

Cash and cash equivalents

Cash and cash equivalents comprises cash balances and bank balances.

ACCOUNTING POLICIES

Tax payable and deferred tax

Current tax liabilities and receivable current tax are recognised in the balance sheet as the calculated tax on the taxable income for the year, adjusted for tax on the taxable income for previous years and taxes paid on account.

Deferred tax is measured on the temporary differences between the carrying amount and the tax value of assets and liabilities.

Deferred tax assets, including the tax value of tax loss carry-forwards, are measured at the expected realisable value of the asset, either by set-off against tax on future earnings or by set-off against deferred tax liabilities within the same legal tax entity.

Deferred tax is measured on the basis of the tax rules and tax rates that under the legislation in force on the balance sheet date would be applicable when the deferred tax is expected to crystallise as current tax.

Liabilities

Liabilities are measured at amortised cost, which usually corresponds to nominal value.

Foreign currency translation

The financial statements are presented in USD, based on bookkeeping records expressed in USD. The foreign exchange rate in relation to DKK versus USD on the balance day is 706,08.

Transactions in foreign currencies are translated at the rate of exchange on the transaction date. Exchange differences arising between the rate on the transaction date and the rate on the payment date are recognised in the income statement as a financial income or expense.

Receivables, payables and other monetary items in foreign currencies that are not settled on the balance sheet date are translated at the exchange rate on the balance sheet date. The difference between the exchange rate on the balance sheet date and the exchange rate at the time of occurrence of the receivables or payables is recognised in the income statement as financial income or expenses.

CASH FLOW STATEMENT

With reference to section 86(4) of the Danish Financial Statements Act., no cash flow statement is prepared for the company, as its cash flows are reflected in the consolidated cash flow statement.

Addendum to note 5 - Fixed asset investments

Entity name	Equity Currency thousand	Profit/(loss) Currency thousand	Owner- ship	Country of domicile	Currency	Source of financial information
BCK Holdings S.à.r.l.	2.015.842	-18.291	100%	Luxembourg	EUR	Financial statements 2016
DH Luxemburg SARL	-57	-12	100%	Luxembourg	EUR	Financial statements 2015
Beckman Coulter, Inc.	8.887.091	-903.478	78%	US	USD	Internal financial reporting
AB Sceix LLC	902.369	-55.519	100%	US	USD	Internal financial reporting
Orange Holding Corp	0	0	100%	US	USD	No group financial reporting are available
Phenomenex Inc	0	0	100%	US	USD	No group financial reporting are available
Inventx	0	0	100%	US	USD	No group financial reporting are available
Phenova	0	0	100%	US	USD	No group financial reporting are available
Phenomenex India Holdings LLC	0	0	100%	India	USD	No group financial reporting are available
BCK Luxembourg S.à.r.l.	24.572	-15	100%	Luxembourg	EUR	Financial statements 2015
Beckman Australia ApS	205.073	-27.248	100%	Denmark	DKK	Financial statements 2016
Beckman Coulter (Israel) Ltd.	1.404	269	100%	Israel	ILS	Internal financial reporting
Beckman Coulter (U.K.) Pension Trustees Limited	0	0	100%	UK	USD	No group financial reporting are available
Beckman Coulter AB	251.407	4.225	100%	Sweden	SEK	Internal financial reporting
Beckman Coulter Biomedical, LLC	0	0	100%	US	USD	No group financial reporting are available
Beckman Coulter Chile Limitada	805.016	335.714	100%	Chile	CLP	Internal financial reporting
Beckman Coulter Danmark ApS	4.371	-379	100%	Denmark	USD	Financial statements 2015
Beckman Coulter de Mexico, S.A. de C.V.	60.077	12.929	100%	Mexico	USD	Internal financial reporting
Beckman Coulter de Venezuela, S.A.	-313	2	100%	Venezuela	USD	Internal financial reporting
Beckman Coulter do Brasil Comércio e Importação...	174.120	-50.637	100%	Brazil	BRL	Internal financial reporting
Leica do Brasil Importação e Comercio Ltda	40.851	-6.468	35%	Brazil	BRL	Internal financial reporting
Beckman Coulter Genomics Inc.	63.041	26.162	100%	US	USD	Internal financial reporting
Beckman Coulter Holding S.à.r.l.	68.871	-26	100%	Luxembourg	EUR	Financial statements 2015
Beckman Coulter Ireland Inc.	34.990	8.160	100%	Ireland	EUR	Financial statements 2015
Beckman Coulter España, S.A.U.	30.986	92	100%	Spain	EUR	Internal financial reporting
Beckman Coulter Korea Ltd.	55.871.289	5.084.485	100%	Korea	KRW	Internal financial reporting
Beckman Coulter Nederland B.V.	68.685	1.909	100%	Netherlands	EUR	Financial statements 2015
BCN Holdco Limited	23.148	-23	100%	UK	GBP	Financial statements 2015
Beckman Coulter d.o.o.	171.253	5.215	100%	Croatia	HRK	Internal financial reporting
Beckman Coulter Finland Oy	3.679	197	100%	Finland	EUR	Internal financial reporting
Beckman Coulter Hong Kong Limited	358.889	-416	35%	Hong Kong	USD	Internal financial reporting
BCHK UK Limited	-293	-293	100%	UK	GBP	Financial statements 2015
Beckman Coulter (Dallan) Software Co.	119.202	77.279	100%	China	CNY	Financial statements 2016
Beckman Coulter Biotechnology (Suz)	80.427	103.953	100%	China	CNY	Financial statement 2016
Beckman Coulter Commercial Enterprise (China) C...	276.764	216.824	100%	China	CNY	Financial statements 2015
Beckman Coulter International Trading (Shanghai)...	77.703	62.019	100%	Shanghai	CNY	Internal financial reporting
Beckman Coulter Laboratory Systems (Suzhou) Co....	806.092	234.434	100%	China	CNY	Financial statements 2016

Addendum to note 5 - Fixed asset investments

Entity name	Equity Currency thousand	Profit/(loss) Currency thousand	Owner- ship	Country of domicile	Currency	Source of financial information
Tianjin Bonna-Agela Technologies Co., Ltd.	49.914	11.604	100%	China	CNY	Financial statements 2015
Bonna-Agela Technologies Inc.	302	23	100%	US	USD	Internal financial reporting
Bonna-Agela India Pvt. Ltd.	0	0	50%	India	USD	No group financial reporting are available
Chengdu Najie Technologies Co., Ltd.	0	0	100%	China	USD	No group financial reporting are available
Shanghai Qianfen Chromatography Technologies Co., Ltd.	0	0	100%	Shanghai	USD	No group financial reporting are available
DH Alpha Limited	-147.830	-78.819	100%	UK	GBP	Financial statements 2015
DH Omega Ltd.	1.724.365	75.739	100%	UK	GBP	Financial statements 2015
GL UK Holdings Limited	60.942	404	46%	UK	GBP	Financial statements 2015
DH Cambridge Holdings Limited	166.666	-457	100%	UK	GBP	Financial statements 2015
Moonsilk Holdings Limited	137.000	0	100%	UK	GBP	Financial statements 2015
GNZ Holdings limited	85.739	33	100%	UK	GBP	Financial statements 2015
KUK Holdings Limited	145.828	2.710	100%	UK	GBP	Internal financial reporting
Molecular Devices (UK) Limited	6.981	951	85%	UK	GBP	Financial statements 2015
Beckman Coulter India Private Limited	3.979.685	373.635	100%	India	INR	Internal financial reporting
Beckman Coulter Magyarország Kft	4.613.766	63.119	100%	Hungary	HUF	Internal financial reporting
Beckman Coulter Malaysia Sdn Bhd	35.239	1.947	100%	Malaysia	MYR	Internal financial reporting
Beckman Coulter Polska sp. z.o.o.	58.186	5.004	100%	Poland	PLN	Internal financial reporting
Beckman Coulter South Africa (Proprietary) Limited	438.488	52.068	100%	South Africa	ZAR	Internal financial reporting
DH SOUTH AFRICA TRUST SUBSIDIARY PROPRIETARY	0	0	100%	South Africa	USD	No group financial reporting are available
Beckman Coulter Portugal Unipessoal Lda.	1.230	498	100%	Portugal	EUR	Internal financial reporting
Beckman Coulter Puerto Rico Inc.	26.735	-264	100%	US	USD	Internal financial reporting
Beckman Coulter Argentina S.A.	9.340	-725	95%	Argentina	USD	Internal financial reporting
Beckman Coulter Servicios, S. de R.L. de C.V.	4.345	3.250	100%	Mexico	MXN	Internal financial reporting
AB Sciex SA de CV	36.190	5.124	100%	Mexico	MXN	Internal financial reporting
Beckman Coulter Singapore Pte. Ltd.	17.715	1.041	100%	Singapore	SGD	Financial statements 2015
Beckman Coulter Taiwan Inc.	46.119	1.699	100%	Taiwan	USD	Internal financial reporting
Beckman Holdings Limited	50.352	-466	43%	UK	GBP	Financial statements 2015
Beckman Coulter Biyomedikal Ürünler Sanayi ve T...	265.515	9.895	76%	Turkey	TRY	Internal financial reporting

Addendum to note 5 - Fixed asset investments

Entity name	Equity	Profit/(loss)	Owner-ship	Country of domicile	Currency	Source of financial information
	Currency thousand	Currency thousand				
Cepheid	4.038.577	-61.423	100% US		USD	Internal financial reporting
Cepheid AB	12.217	9.858	100% Sweden		USD	Internal financial reporting
Cepheid benelux BVBA	12	-10	100% Belgium		EUR	Financial statements 2015
Cepheid Brasil Exportacao e Comercio de Produtos de Diagnosticos Ltda.	4.381	1.063	100% Brazil		BRL	Financial statements 2016
Cepheid Canadian Corporation	0	0	100% US		USD	No group financial reporting are available
Cepheid Europe SAS	4.643	5.327	100% France		USD	Internal financial reporting
Cepheid HBDC SAS	3.874	4.443	100% US		USD	Internal financial reporting
Cepheid GK	141	-38	100% Japan		USD	Internal financial reporting
Cepheid GmbH	3.962	-4.829	100% Germany		USD	Internal financial reporting
Cepheid HBDC	0	0	100% US		USD	No group financial reporting are available
Cepheid Holdings Pty Limited	394	27	100% Australia		USD	Internal financial reporting
Cepheid India Private Limited	702	519	100% India		USD	Internal financial reporting
Cepheid Lodi, LLC	0	0	100% US		USD	No group financial reporting are available
Cepheid Limited	2.486	0	100% Hong Kong		USD	Internal financial reporting
Cepheid (Shanghai) Commerce and trade	2.763	399	100% Shanghai		USD	Internal financial reporting
Cepheid (Shanghai) Diagnostics Co. Ltd	-90	-211	100% Shanghai		USD	Internal financial reporting
Cepheid Proprietary Limited	3.812	-4.663	100% South Africa		USD	Internal financial reporting
Cepheid S.r.l.	1.239	11	100% Italy		EUR	Financial statements 2016
Cepheid Singapore Pte. Ltd.	57	59	100% Singapore		USD	Internal financial reporting
Cepheid UK Limited	1.154	0	100% UK		GBP	Financial statements 2015
DH Life Sciences LLC	0	0	100% US		USD	Internal financial reporting
Hybritech Incorporated	221.725	14.664	100% US		USD	Internal financial reporting
Hybrigenetics Cancer Research Incorporated	1.000	17	100% US		USD	Internal financial reporting
Hybritech International Incorporated	-19.605	0	100% US		USD	Internal financial reporting
IAF Corporation Pty Ltd	0	0	100% Australia		USD	No group financial reporting are available
Diagnostic Systems Laboratories Australia Pte	3.304	1.053	100% Australia		AUD	Internal financial reporting
Inhybin Pty Limited	0	0	100% Australia		USD	No group financial reporting are available
Iris International Europe GmbH	378	-2	100% Switzerland		CHF	Financial statements 2015
Beckman Coulter Eurocenter SA	59.102	2.032	100% Switzerland		CHF	Financial statements 2015
BECKMAN COULTER INTERNATIONAL SA	244.172	1.816	100% Saudi Arabia		USD	Internal financial reporting
BECKMAN SAUDI ARABIA CO LTD (50%)	3.423	-359	75% Saudi Arabia		SR	Financial statements 2015
Iris International Inc.	310.897	-15.928	100% US		USD	Internal financial reporting
Arista Molecular, Inc	3.752	-58	100% US		USD	Internal financial reporting
KMB S.a.r.l.	364.002	90.456	92% Luxembourg		EUR	Financial statements 2015
X-Rite Holdings SARL	572.457	50.879	73% Luxembourg		USD	Financial statements 2015
Beckman Luxembourg SARL	320.558	-17	100% Luxembourg		EUR	Financial statements 2015
Beckman Finance Sarl	347.529	-15	100% Luxembourg		EUR	Financial statements 2015
WA3 SaRL	347.562	-15	100% France		EUR	Financial statements 2015
Beckman Coulter Holding ApS	350.695	343	100% Denmark		EUR	Financial statements 2016

Addendum to note 5 - Fixed asset investments

Entity name	Equity Currency thousand	Profit/(loss) Currency thousand	Owner- ship	Country of domicile	Currency	Source of financial information
X-RITE EUROPE GMBH (FKA XEG 1234 GMBH)	17.793	-696	82%	Switzerland	CHF	Financial statements 2015
VIDEOJET TECHNOLOGIES SUISSE GMBH (FKA WILET SYSTEM)	4.977	66	100%	Switzerland	CHF	Financial statements 2015
X-RITE ASIA PACIFIC LIMITED	40.372	-1.342	100%	Hong Kong	USD	Internal financial reporting
X-Rite India Private limited	7.102	1.265	100%	India	INR	Internal financial reporting
X-Rite Switzerland GMBH	24.537	352	100%	Switzerland	CHF	Financial statements 2015
NBH Switzerland Holding SARL	142.325	-36	28%	Luxembourg	USD	Financial statements 2015
Leica Microsystems Inc.	90.148	-12.448	100%	US	USD	Internal financial reporting
Bioprogen, Inc.	-5.027	-1.721	100%	US	USD	Internal financial reporting
Devicor Medical Products Holdings, Inc.	0	0	100%	US	USD	Internal financial reporting
Devicor Medical Products, Inc.	389.333	-39.913	100%	US	USD	Internal financial reporting
Artemis Medical, Inc.	0	0	100%	US	USD	Internal financial reporting
Devicor Medical Canada, Inc.	864	3	100%	Canada	CAD	Internal financial reporting
Devicor Medical Cayman Limited	175	-223	100%	Cayman	ILS	Internal financial reporting
Devicor Medical H.K. Limited	-1.163	-286	100%	Hong Kong	USD	Internal financial reporting
Devicor Medical Device (Shanghai) Co., Ltd.	56.258	8.116	100%	Shanghai	CNY	Internal financial reporting
Devicor Medical Europe GmbH	817	2.145	100%	Germany	EUR	Internal financial reporting
Devicor Medical France SAS	32.106	5.051	100%	France	USD	Internal financial reporting
Devicor Medical Germany GmbH	0	-497	100%	Germany	EUR	Financial statements 2015
Devicor Medical Holdings LLC	0	0	100%	US	USD	Internal financial reporting
Devicor Medical Italy S.r.l.	5.382	227	44%	Italy	EUR	Financial statements 2016
Devicor Medical Japan K.K.	0	0	100%	Japan	USD	No group financial reporting are available
Devicor Medical Poland sp. z o.o.	1.388	248	100%	Poland	PLN	Internal financial reporting
Devicor Medical Products de Mexico, S. de R.L. ...	141.549	9	99%	Mexico	EUR	Internal financial reporting
Devicor Medical Products Servicios, S. de R.L. ...	-2.262	454	99%	Mexico	EUR	Internal financial reporting
Devicor Medical Puerto Rico LLC	0	0	100%	Puerto Rico	USD	Internal financial reporting
Devicor Medical UK Limited	101	295	100%	UK	GBP	Financial statements 2015
Devicor Medical Korea Limited	-73.999	605.396	100%	Korea	KRW	Internal financial reporting
Leica biosystems Richmond Inc	0	0	100%	US	USD	Internal financial reporting
Lumigen, Inc	293.014	29.302	100%	US	USD	Internal financial reporting
Molecular Devices, LLC	0	0	100%	US	USD	Internal financial reporting
Blueshift Biotechnologies, LLC	11.702	0	100%	US	USD	Internal financial reporting
Molecular Devices (Germany) GmbH	3.011	353	59%	Germany	EUR	Financial statements 2015
Molecular Devices (Hong Kong) Limited	14.911	1.572	100%	Hong Kong	USD	Financial statements 2015
Molecular Devices (Shanghai) Limited	57.981	8.041	100%	Shanghai	CNY	Internal financial reporting
Molecular Devices Instrumentação do Brasil Ltda.	1.172	0	99%	Brazil	EUR	Internal financial reporting
Molecular Devices Korea, LLC	2.582.685	238.309	100%	Korea	KRW	Internal financial reporting

Addendum to note 5 - Fixed asset investments

Entity name	Equity Currency thousand	Profit/(loss) Currency thousand	Owner- ship	Country of domicile	Currency	Source of financial information
Leica Microsystemes SAS	4.074	2.754	100%	France	EUR	Financial statements 2015
Beckman Coulter France ApS	1.484	-348	100%	Denmark	EUR	Financial statements 2016
Beckman Coulter France S.A.S.	151.198	8.446	100%	France	EUR	Financial statements 2016
Immunotech SAS	44.675	11.961	100%	France	EUR	Financial statements 2016
Immunotech Sro	1.721.255	60.135	100%	Czech Republic	CZK	Internal financial reporting
Beckman Coulter Ceska republika s.r.o.	665.365	47.807	100%	Czech Republic	CZK	Financial statements 2015
Beckman Coulter Limited Liability Company	1.981.410	314.881	99%	Rusia	RUR	Internal financial reporting
Beckman Coulter Slovenska republika s.r.o.	14.168	-667	100%	Slovakia	EUR	Internal financial reporting